ArticleAllergy2019
Sublingual immunotherapy with recombinant Mal d 1 downregulates the allergen-specific Th2 response.
Claudia Kitzmüller et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
8 papers cite it
this papertrialcites it